natgillin/translations-raw huggingface dataset:
DuoTrav has no or negligible influence on the ability to drive and use machines.
Zdravilo DuoTrav nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
DuoTrav is a combination of 2 active substances.
Zdravilo DuoTrav je kombinacija dveh zdravilnih učinkovin.
DuoTrav is indicated in adults for the decrease of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues (see section 5.1).
Zdravilo DuoTrav je indicirano pri odraslih za znižanje očesnega tlaka pri bolnikih z glavkomom z odprtim zakotjem ali očesno hipertenzijo, ki se ne odzivajo zadostno na topikalne zaviralce adrenergičnih receptorjev beta ali prostaglandinske analoge (glejte poglavje 5.1).
DuoTrav is not to be used by children and adolescents under 18 years of age.
Zdravila DuoTrav ne smejo uporabljati otroci in mladostniki, mlajši od 18 let.
DuoTrav must not be used in women who may become pregnant unless adequate contraceptive measures are in place (see section 5.3).
Zdravila DuoTrav ne smejo uporabljati ženske, ki bi lahko zanosile, če nimajo ustrezne kontracepcijske zaščite (glejte poglavje 5.3).
DuoTrav reduced the pressure inside the eye by about a third in all of the studies (the average reduction was about 8-10 mmHg).
V vseh študijah je zdravilo DuoTrav tlak znotraj očesa znižalo za približno tretjino (povprečno znižanje je bilo približno 8–10 mmHg).
DuoTrav travoprost / timolol
DuoTrav travoprost/timolol
DuoTrav was more effective at reducing the pressure inside the eye than timolol on its own, or travoprost on its own.
DuoTrav je bilo pri zniževanju tlaka znotraj očesa učinkovitejše od timolola ali travoprosta, uporabljenih samostojno.
Dupuytren’s contracture is a condition where one or more fingers are bent forwards toward the palm and cannot be fully straightened.
Dupuytrenova kontraktura je bolezen, pri kateri se en ali več prstov upogne naprej proti dlani in jih ni mogoče popolnoma iztegniti.
Dupuytren’s contracture: The joint to be treated (MP or PIP) should be confirmed as the volume of solvent required for reconstitution is determined by the type of joint (PIP joint requires a smaller volume for injection).
Dupuytrenova kontraktura: sklep, ki ga boste zdravili (MP ali PIP), je treba potrditi, saj je volumen vehikla, ki je potreben za rekonstitucijo, določen glede na vrsto sklepa (za PIP sklep je potreben manjši volumen za injiciranje).
Dupuytren’s MP joints
Dupuytrenovi MP sklepi
Dupuytren’s PIP joints
Dupuytrenovi PP sklepi
Durable clinical remission#
Trajna klinična remisija#
Durable clinical response¶
Trajni klinični odziv¶
Durable complete symptomatic responsed
trajni popolni simptomatski odzivd
Durable outcomes (Week 48 and Week 96) for patients on the recommended dose ISENTRESS 400 mg twice daily from the pooled studies BENCHMRK 1 and BENCHMRK 2 are shown in Table 2.
V preglednici 2 so prikazani dolgotrajni izidi (po 48 in 96 tednih) zdravljenja s priporočenim odmerkom zdravila ISENTRESS v odmerku 400 mg dvakrat na dan iz združenih študij BENCHMRK 1 in BENCHMRK 2.
Durable outcomes (Week 48 and Week 96) for patients on the recommended dose ISENTRESS 400 mg twice daily from the pooled studies BENCHMRK 1 and BENCHMRK 2 are shown in Table 3.
V preglednici 3 so prikazani dolgotrajni izidi (po 48 in 96 tednih) zdravljenja s priporočenim odmerkom zdravila ISENTRESS v odmerku 400 mg dvakrat na dan iz združenih študij BENCHMRK 1 in BENCHMRK 2.
Durable outcomes (Week 48 and Week 96) for patients on the recommended dose ISENTRESS 400 mg twice daily from the pooled studies BENCHMRK 1 and BENCHMRK 2 are shown in Table 4.
V preglednici 4 so prikazani dolgotrajni izidi (po 48 in 96 tednih) zdravljenja s priporočenim odmerkom zdravila ISENTRESS v odmerku 400 mg dvakrat na dan iz združenih študij BENCHMRK 1 in BENCHMRK 2.
Durable response rate
Delež trajnega odziva
Durable tumour & symptomatic response (independent review)
trajni tumorski in simptomatski odziv (po oceni neodvisnih ocenjevalcev)
Durable tumour & symptomatic response (investigator review)
trajni tumorski in simptomatskega odziv (po oceni raziskovalcev)
Durable tumour & symptomatic response (investigator review)
trajni tumorski in simptomatski odziv (po oceni neodvisnih ocenjevalcev)
Duration (hours): Oxyglobin levels over 1 g/dl**
Trajanje(ure): koncentracije Oxyglobina nad 1 g/dl
Duration and frequency of treatment
Trajanje in pogostnost zdravljenja
Duration hours): Oxyglobin levels over 1 g/dL**
Trajanje (ure): koncentracije Oxyglobina nad 1 g/dL
Duration of action (hr) GIRmax (mg/kg/min)
Trajanje delovanja (h) GIRmax (mg/kg/min)
Duration of administration
trajanje dajanja zdravila
Duration of Atrial Fibrillation
Trajanje atrijske fibrilacije
Duration of current severe clinical TMA manifestation
Trajanje nedavne resne klinične manifestacije TMA
Duration of durable complete symptomatic response (days) median (min, max)
trajanje trajnega popolnega simptomatskega odziva (dnevi), mediana vrednost (najmanjša , največja vrednost)
Duration of empirical therapy should be based on the patient’s clinical response.
Trajanje empiričnega zdravljenja mora temeljiti na kliničnem odzivu bolnika.
Duration of immunity against Newcastle disease: 9 week of age.
Trajanje imunosti proti Newcastle bolezni: 9 teden starosti.
Duration of immunity against Newcastle disease: 9 weeks of age.
Trajanje imunosti proti Newcastle bolezni: 9 teden starosti.
Duration of immunity in ducks : 14 weeks after the second injection.
Čas trajanja imunske zaščite pri racah: 14 tednov od druge injekcije
Duration of immunity induced by the vaccination scheme:
Čas trajanja imunosti, ki ga spodbudi predvideni razpored cepljenja:
Duration of immunity: 12 months after completion of the primary vaccination scheme
Trajanje imunosti: 12 mesecev po končanem osnovnem cepljenju.
Duration of immunity: 12 months after completion of the primary vaccination scheme.
Trajanje imunosti: 12 mesecev po končanem osnovnem cepljenju.
Duration of immunity: 12 months.
Trajanje imunosti: 12 mesecev
Duration of immunity: 19 weeks post-vaccination
Trajanje imunosti: 19 tednov po cepljenju.
Duration of immunity: 23 weeks after vaccination (PCV2)
Trajanje imunosti: 23 tednov po cepljenju (PCV2).
Duration of immunity: 23 weeks after vaccination.
Trajanje imunosti: 23 tednov po cepljenju
Duration of immunity: 23weeks after vaccination (PCV2)
Trajanje imunosti: 23 tednov po cepljenju (PCV2).
Duration of immunity: 4 months in pigs vaccinated between the age of 56 and 96 days and
Trajanje imunosti: 4 mesece pri prašičih cepljenih v starosti med 56 in 96 dni
Duration of immunity: 6 months after completion of the basic vaccination scheme.
Trajanje imunosti: 6 mesecev po zaključku osnovnega cepljenja.
Duration of immunity: 6 months after the last (re-)vaccination .
Trajanje imunosti: šest mesecev po zadnji (re-)vakcinaciji.
Duration of immunity: 6 months after the last (re-)vaccination.
Trajanje imunosti: šest mesecev po zadnji (re-)vakcinaciji.
Duration of immunity: 6 months after vaccination.
Trajanje imunosti: 6 mesecev po cepljenju
Duration of immunity: A single vaccination is sufficient to provide protection during the risk period of infection with Marek’s disease.
Trajanje imunosti: enkratno cepljenje zadostuje za zaščito v obdobju tveganja okužbe z Marekovo boleznijo.
Duration of immunity: at least 14 weeks after vaccination.
Trajanje imunosti: najmanj 14 tednov po cepljenju.
Duration of immunity: at least 6 months
Trajanje imunosti: vsaj 6 mesecev.
Duration of immunity: At least three years following the primary vaccination course for rabies.
Trajanje imunosti: Vsaj tri leta po osnovnem cepljenju proti stekline.
Duration of immunity: has not been established.
Trajanje imunosti: ni bilo ugotovljeno.
Duration of immunity: ILT: 60 weeks,
Trajanje imunosti: ILT: 60 tednov
Duration of immunity: one year after the primary vaccination for all components.
Trajanje imunosti: eno leto po prvem cepljenju za vse sestavine.
Duration of immunity: up to 3 months.
Trajanje imunosti: do 3 mesece
Duration of immunity: up to 5 weeks after transfer of passive antibodies through colostrum intake.
Trajanje imunosti: do 5 tednov po prenosu pasivnih protiteles s kolostrumom.
Duration of interference after a 5 g dose
Trajanje motnje po 5-gramskem odmerku
Duration of intracranial response, median, months (95% CI)
Trajanje intrakranialnega odziva, mediana, meseci (95 % IZ)
Duration of MaHR (%; Kaplan-Meier estimates)
Trajanje dobrega hematološkega odziva (%; Kaplan-Meierjeva ocena)
Duration of objective response (months)
Trajanje objektivnega odgovora (meseci)
Duration of protection is uncertain in elderly persons, therefore a booster dose (third dose) should be considered before any further exposure to JE virus.
Ker je zaščita pri starostnikih nezanesljiva, morajo pred nadaljnjo izpostavljenostjo virusu japonskega encefalitisa prejeti dodatni odmerek (tretji).
Duration of response
Trajanje odziva
Duration of Response (DoR)
Trajanje odziva
Duration of response (DOR) (IRC- assessed)
Trajanje odziva (DOR) (po oceni IRC)
Duration of Response (DoR)3
Trajanje odziva (DoR)3
Duration of Response †^ n=
Trajanje odgovora †^ n =
Duration of response  (months)h
Trajanje odziva  (meseci)h
Duration of response*
trajanje odgovora
Duration of response*
trajanje odziva
Duration of Response**, CR or PR (Months)
Trajanje odziva**, CR ali PR
Duration of response, median, months (95% CI)
Trajanje odziva, mediana, meseci (95 % IZ)
Duration of Response, mediana [95% CI] (weeks)
Trajanje odziva, medianaa [95 % IZ] (tedni)
Duration of response, months, median (95% CI)
trajanje odziva, meseci, mediana (95 % IZ)
Duration of response,d months, median (95% CI)
trajanje odziva,d meseci, mediana (95 % IZ)
Duration of Responseb [median (95% CI)] weeks
Trajanje odzivab [mediana (95 % IZ)] v tednih
Duration of Responsec [median (95% CI)] weeks
Trajanje odzivac [mediana (95 % IZ)] v tednih
Duration of the procedure
Trajanje zdravljenja
Duration of the treatment with Imnovid
Trajanje zdravljenja z zdravilom Imnovid
Duration of the treatment with Revlimid
Trajanje zdravljenja z zdravilom Revlimid
Duration of the treatment with Vimpat
Trajanje zdravljenja z zdravilom Vimpat
Duration of the treatment with Vimpat solution for infusion
Trajanje zdravljenja z zdravilom Vimpat raztopina za infundiranje
Duration of treatment
Dolžina zdravljenja
Duration of treatment
Trajanje zdravljenja:
Duration of treatment
Tímalengd meðferðar
Duration of treatment
vred- nost p
Duration of treatment depends on how the patient responds to treatment.
Trajanje zdravljenja je odvisno od tega, kako se bolnik odzove na zdravljenje.
Duration of treatment in children and adolescents
Dolžina zdravljenja pri otrocih in mladostnikih
Duration of treatment of invasive candidiasis should be based upon the patient’s clinical and microbiological response.
Trajanje zdravljenja invazivne kandidiaze mora temeljiti na bolnikovem kliničnem in mikrobiološkem odzivu.
Duration of treatment should be based on the patient’s clinical response.
Trajanje zdravljenja mora temeljiti na kliničnem odzivu bolnika.
Duration of treatment will be dependent on the response observed.
Čas zdravljenja je odvisen od odziva.
Duration of treatment – dual therapy with Pegasys and ribavirin
Trajanje zdravljenja – dvojno zdravljenje z zdravilom Pegasys in ribavirinom
Duration of treatment – Naïve patients
Dolžina zdravljenja – nezdravljeni bolniki
Duration of treatment – Naïve patients
Dolžina zdravljenja – predhodno nezdravljeni bolniki
Duration of treatment – Naïve patients
Dolžina zdravljenja – predhodno nezdravljeni bolniki:
Duration of treatment – Naïve patients
Trajanje zdravljenja predhodno nezdravljenih bolnikov:
Duration of treatment – Previously treated adults with prior partial or prior null response Treatment with INCIVO must be initiated in combination with peginterferon alfa and ribavirin and administered for 12 weeks, followed by peginterferon alfa and ribavirin therapy alone (without INCIVO) for a total treatment duration of 48 weeks (see figure 2).
Zdravljenje z zdravilom INCIVO je treba uvesti v kombinaciji s peginterferonom alfa in ribavirinom ter ga izvajati 12 tednov, temu naj sledi zdravljenje samo s peginterferonom alfa in ribavirinom (brez zdravila INCIVO) v skupnem trajanju zdravljenja 48 tednov (glejte sliko 2).
Duration of treatment – Retreatment
Dolžina zdravljenja – ponovno zdravljenje
Duration of treatment – Retreatment
Trajanje ponovnega zdravljenja:
Duration of treatment – Retreatment
Trajanje zdravljenja – ponovno zdravljenje:
Duration of treatment – Treatment-naïve adults and prior treatment relapsers
Trajanje zdravljenja – nezdravljeni odrasli in bolniki, ki so po predhodnem zdravljenju ponovno zboleli
Duration of treatment –dual therapy with Pegasys and ribavirin
Trajanje zdravljenja – dvojno zdravljenje z zdravilom Pegasys in ribavirinom
Duration of treatment–dual therapy with Pegasys and ribavirin
Trajanje zdravljenja – dvojno zdravljenje z zdravilom Pegasys in ribavirinom
Duration of tumour & symptomatic response (days) - independent review; median (min, max)
trajanje tumorskega in simptomatskega odziva (dnevi) - po oceni neodvisnih ocenjevalcev; mediana vrednost (najmanjša , največja vrednost)
Duration PD [yrs (SD)]
Trajanje PB [let (SD)]
During 12 months’ monotherapy treatment with LUMIGAN 0.3 mg/ml in adults, versus timolol, mean change from baseline in morning (08:00) intraocular pressure ranged from -7.9 to -8.8 mm Hg.
Med 12 mesečnim zdravljenjem odraslih z zdravilom LUMIGAN 0,3 mg/ml v monoterapiji v primerjavi s timololom, so povprečne spremembe z osnovne vrednosti očesnega tlaka zjutraj (08:00) znašale med –7,9 do –8,8 mm Hg.
During 24 hours following administration of a single radiolabelled [3H]­liraglutide dose to healthy subjects, the major component in plasma was intact liraglutide.
V 24 urah po aplikaciji enega odmerka radioaktivno označenega [3H]-liraglutida zdravim osebam je bila glavna komponenta v plazmi nespremenjen liraglutid.
During 52 weeks of studies UC-I and UC-II, lower rates of all-cause hospitalisations and UC-related hospitalisations were observed for the adalimumab-treated arm compared to the placebo arm.
V 52 tednih študij UC-I in UC-II so opazili nižjo stopnjo hospitalizacij iz vseh razlogov in hospitalizacij, povezanih z ulceroznim kolitisom, pri skupini, zdravljeni z adalimumabom, v primerjavi s placebo skupino.
During 52 weeks of studies UC-I and UC-II, lower rates of all-cause hospitalisations and UC-related hospitalisations were observed for the adalimumab-treated arm compared to the placebo.
V 52 tednih študij UC-I in UC-II so opazili nižjo stopnjo hospitalizacij iz vseh razlogov in hospitalizacij, povezanih z ulceroznim kolitisom, pri skupini, zdravljeni z adalimumabom, v primerjavi s placebo skupino.
During a cumulative review of severe skin reaction events, three cases of Stevens-Johnson syndrome (SJS) were identified where a causal association is assessed as at least possible including two reports with reasonable time to onset and biopsy confirmed.
Med kumulativnim pregledom dogodkov resnih kožnih reakcij so ugotovili tri primere Stevens- Johnsonovega sindroma (SJS), pri katerih so ocenili vzročno povezavo kot vsaj možno, vključno z dvema poročiloma, pri katerih je bil smiseln čas do začetka in sta bila potrjena z biopsijo.
During a flu pandemic, Ebilfumin can also be used to treat or prevent flu in babies below one year of age.
Med pandemijo gripe se lahko zdravilo Ebilfumin uporablja tudi za zdravljenje ali preprečevanje gripe pri dojenčkih, mlajših od enega leta.
During a flu pandemic, Tamiflu can also be used to prevent flu in babies below one year of age.
Med pandemijo gripe se lahko zdravilo Tamiflu uporablja tudi za preprečevanje gripe pri dojenčkih, mlajših od enega leta.
During a pandemic, the virus strain in Foclivia will have to be replaced by the strain causing the pandemic before the vaccine can be used.
Med pandemijo bo sev virusa v zdravilu Foclivia nadomeščen s sevom, ki povzroča pandemijo, preden bo cepivo mogoče uporabljati.
During a pandemic, the virus strain in Pandemic Influenza Vaccine H5N1 Baxter AG will have to be replaced by the strain causing the pandemic before the vaccine can be used.
Med pandemijo bo treba sev virusa v cepivu Pandemic Influenza Vaccine H5N1 Baxter AG nadomestiti s sevom, ki povzroča pandemijo, preden bo cepivo mogoče uporabiti.
During a period of 24 hours with once-daily treatment, the glucose-lowering effect of Tresiba, in contrast to insulin glargine, was evenly distributed between the first and second 12 hours (AUCGIR,0-12h,SS/AUCGIR,total,SS = 0.5).
V nasprotju z insulinom glargin je znižanje koncentracije glukoze med uporabo zdravila Tresiba enkrat na dan v 24-urnem obdobju enakomerno porazdeljeno med prvimi in drugimi 12 urami (AUCGIR, 0-12 h, SS/AUCGIR, skupaj,
During a pharmacokinetic study with Imiquimod 3.75% cream following application of 2 sachets once daily (18.75 mg imiquimod/day) for up to three weeks to the entire face and/or scalp (approximately 200 cm2), low systemic absorption of imiquimod was observed in patients with AK.
Med farmakokinetično študijo z imikvimod 3,75 % kremo so pri bolnikih z AK, ki so do tri tedne na celotni obraz in/ali lasišče (približno 200 cm2) nanašali 2 vrečici (18,75 mg imikvimoda/dan) na dan, opazili nizko sistemsko absorpcijo imikvimoda.
During a refill procedure, a very small amount of insulin may be deposited subcutaneously, possibly resulting in hypoglycaemia.
Med ponovnim polnjenjem lahko zelo majhna količina insulina pride v podkožje; to lahko povzroči hipoglikemijo.
During a refill procedure, a very small amount of insulin may be deposited subcutaneously, possibly resulting in hypoglycemia.
Med ponovnim polnjenjem lahko zelo majhna količina pride v podkožje; to lahko povzroči hipoglikemijo.
During a short break in taking the medicine, the amount of virus in your blood may increase.
Že med kratko prekinitvijo jemanja zdravila se lahko poveča količina virusa v krvi.
During abdominal surgery, 95% of the patients had no bleeding 10 minutes after treatment with Evicel (63 out of 66), compared with 81% of the patients treated with Surgicel (56 out of 69).
95 % (63 od 66) bolnikov krvavitev prenehala v desetih minutah po zdravljenju z zdravilom Evicel, v primeru zdravljenja s snovjo Surgicel pa je krvavitev prenehala pri 81 % (56 od 69) bolnikov.
During administration of micafungin, anaphylactic/anaphylactoid reactions including shock may occur.
V času zdravljenja z mikafunginom se lahko pojavijo anafilaktične/anafilaktoidne reakcije, vključno s šokom.
During all clinical studies with NovoEight, a total of 30 adverse reactions were reported in 19 of 214 patients exposed to NovoEight.
V vseh kliničnih študijah z zdravilom NovoEight je bilo skupno opisanih 30 neželenih učinkov pri 19 od 214 bolnikov, izpostavljenih zdravilu NovoEight.
During an 8-week baseline period, patients had to experience 4 partial onset seizures per 28 days.
Med 8- tedenskim izhodiščnim obdobjem so se morali bolnikom pojaviti  4 napadi s parcialnim začetkom v 28 dneh.
During an accumulated exposure of more than 54,000 days (corresponding to 342 patient years), no factor VIII inhibitor development was observed in the phase 3a clinical trials in previously treated patients.
Med skupno izpostavljenostjo več kot 54.000 dni (to ustreza 342 bolnik-letom) v kliničnih preskušanjih faze 3a pri predhodno zdravljenih bolnikih niso opazili pojava zaviralcev faktorja VIII.
During an embryo-fetal development study where siltuximab was administered intravenously to pregnant cynomolgus monkeys (gestation day 20 – 118) at doses of 9.2 and 46 mg/kg/week, no maternal or fetal toxicity was observed.
V študiji embriofetanega razvoja, v kateri so brejim opicam cinomolgus (od 20. do 118. dne brejosti) intravensko injicirali siltuksimab v odmerkih 9,2 oziroma 46 mg/kg/teden, niso opazili toksičnih učinkov na mater ali na plod.
During an open-label extension period the percentage of patients meeting the composite stability endpoint was maintained at 87.4% after 24 months of treatment with Cerdelga.
V odprtem, podaljšanem obdobju je bil po 24. mesecih zdravljenja z zdravilom Cerdelga odstotek bolnikov, ki so dosegali sestavljeno končno točko stabilnosti, vzdrževan pri 87,4 %.
During an open-label extension period, patients who continued to receive Cerdelga (n=18) showed further improvements (change from baseline) in haemoglobin level (1.02 g/dL), platelet count (58.16%) and spleen and liver volumes (-44.61% and -11.18% respectively) after 18 months of treatment.
Po 18. mesecih zdravljenja v odprtem, podaljšanem obdobju so pri bolnikih, ki so še naprej prejemali zdravilo Cerdelga (n=18), opazili nadaljnje izboljšave (sprememba od izhodišča) v ravni hemoglobina (1,02 g/dl), številu trombocitov (58,16 %) ter prostornini vranice (-44,61 %) in prostornini jeter (-11,18 %).
During an operation on the eye for cloudiness of the lens (cataract), the iris (the coloured part of the eye) may become floppy during surgery (known as “floppy iris syndrome”) that may lead to eye damage. are aware of having dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood
Med očesno operacijo zaradi zamotnitve očesne leče (katarakta, operacija sive mrene) se lahko zgodi, da šarenica (obarvani del očesa) postane ohlapna (kar imenujemo sindrom ohlapne šarenice) in to lahko povzroči poškodbo očesa. veste, da imate nevarno majhno število določenih tipov belih krvnih celic, ki jih potrebujete za obrambo pred okužbo v krvi.
during an operation, to stop bleeding and to seal the surfaces of internal organs;
pri kirurških posegih za zaustavitev krvavitve in za zapiranje površin notranjih organov;
During and after Simponi treatment
Med in po zdravljenju z zdravilom Simponi
During and after Simponi treatment:
Med zdravljenjem z zdravilom Simponi:
During and after treatment with Zalmoxis the physician must be aware of acute and chronic sign and symptoms of GvHD at any time and ensure that either ganciclovir or valganciclovir is available at ward for early treatment of GvHD.
Med zdravljenjem z zdravilom Zalmoxis in po njem se mora zdravnik ob vsakem trenutku zavedati akutnih in kroničnih znakov in simptomov GvHD in zagotoviti, da sta na oddelku za zgodnje zdravljenje GvHD na voljo ganciklovir ali valganciklovir.
During antipsychotic treatment, improvement in the patient’s clinical condition may take several days to some weeks.
V času antipsihotičnega zdravljenja lahko traja nekaj dni do nekaj tednov, da pride do izboljšanja kliničnega stanja bolnika.
During attempts to overcome
o manjšo izpostavljenost poskušali
During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.
Bolnikom je treba svetovati, naj v času zdravljenja z bisfosfonati sporočijo kakršnekoli bolečine v stegnu, kolku ali dimljah, vsakega bolnika z navedenimi simptomi pa je treba pregledati glede nepopolnega zloma stegnenice.
During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.
Med zdravljenjem z difosfonatom je treba bolnikom naročiti, naj povedo za vsako bolečino v stegnu, kolku ali dimljah, bolnike, ki imajo takšne simptome, pa je treba oceniti glede nepopolnega zloma stegnenice.
During breast feeding.
Med dojenjem.
During capecitabine monotherapy, no adjustment of the starting dose is needed.
Med samostojnim zdravljenjem s kapecitabinom ni treba prilagajati začetnega odmerka.
During capecitabine monotherapy, no adjustment of the starting dose is needed.
Zanje prilagajanje začetnega odmerka pri samostojnem zdravljenju z zdravilom kapecitabin ni potrebno.
During cataract surgery, a condition called intraoperative floppy iris syndrome (IFIS) can happen if you take or have taken Xeplion.
Če ste jemali ali jemljete zdravilo Xeplion, lahko med operacijo sive mrene pride do stanja, ki se imenuje medoperativni sindrom ohlapne šarenice (IFIS).